Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX07 + leucovorin + fluorouracil + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HLX07 + leucovorin + fluorouracil + oxaliplatin is an investigational **combination regimen** composed of HLX07, a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR); leucovorin, a folinic acid; fluorouracil (5-FU), a pyrimidine analog antimetabolite; and oxaliplatin, a platinum-based chemotherapeutic. HLX07 blocks EGFR to inhibit cell proliferation and survival signaling in tumors overexpressing EGFR, commonly esophageal squamous cell carcinoma (ESCC). Leucovorin enhances the cytotoxic effect of fluorouracil, which inhibits thymidylate synthase, blocking DNA synthesis. Oxaliplatin forms DNA crosslinks, inducing cell death. The primary indication under investigation is advanced or metastatic ESCC[1][3][4]. The developer of HLX07 is Shanghai Henlius Biotech.
- Other names
- recombinant anti-EGFR humanized monoclonal antibody injection + modified FOLFOX6
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on HLX07 + leucovorin + fluorouracil + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX07 + leucovorin + fluorouracil + oxaliplatin.